-
Mashup Score: 19Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash - 11 month(s) ago
Transaction to include pelabresib, a late-stage BET inhibitor for myelofibrosis (MF) and tulmimetostat, an early-stage investigational dual inhibitor of EZH2 and EZH1 for solid tumors or lymphomasPelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement with a well-tolerated safety profile in Phase 3 MANIFEST-2 study, when administered in combination with ruxolitinib in JAK inhibitor-naive MF patients1 Basel, February 05, 2024 – Novartis today announced that it has entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (FSE: MOR; NASDAQ: MOR), a Germany-based, global biopharmaceutical company developing innovative medicines in oncology. The acquisition, which is subject to customary closing conditions, including a minimum acceptance threshold of 65% of outstanding shares tendered in the takeover offer and regulatory approvals, further expands and complements Novartis pipeline in
Source: www.novartis.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0
MEDIA & INVESTOR RELEASE Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard-of-care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia Ad hoc announcement pursuant to Art. 53 MEDIA & INVESTOR RELEASE Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.
Source: www.novartis.comCategories: General Medicine News, Hem/OncsTweet-
Chronic Phase Ph+ #CML Rx might have an other option in near future ! Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard‐of‐care TKIs in Phase III trial for newly diagnosed patients with CML @ChronicMyeloid https://t.co/W5rMVewJVj
-
-
Mashup Score: 27Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis - 12 month(s) ago
FDA approval of the company’s second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyondNew 70,000-square foot RLT facility is the company’s largest and most advanced in the world to date and centrally located in the US to maximize access for patients and treatment centers Basel, January 5, 2024— Novartis announced today that it has received approval from the US Food and Drug Administration (FDA) for commercial manufacturing of PluvictoTM (INN: lutetium (177Lu) vipivotide tetraxetan / USAN: lutetium Lu 177 vipivotide tetraxetan) at its new large-scale, state-of-the-art radioligand therapy (RLT) manufacturing facility in Indianapolis, Indiana, United States. The 70,000-square foot site, the company’s second US location, is designed specifically for RLT manufacturing and is now the largest and most advanced Novartis facility of its kind in the world. The Indianapolis site represents the next phase of RLT manufacturing
Source: www.novartis.comCategories: General Medicine News, Hem/OncsTweet-
Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis 👏👏👏 @APCCC_Lugano @thomashopemd @CalaisJeremie @PCFnews @CParkMD https://t.co/5h1OygbTbe
-
-
Mashup Score: 4
Ad hoc announcement pursuant to Art. 53 LR Ad hoc announcement pursuant to Art. 53 LR Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.
Source: www.novartis.comCategories: General Medicine News, NeurologyTweet-
On Dec. 6, the @US_FDA approved iptacopan (trade name FABHALTA) as the 1st oral monotherapy for adults with paroxysmal nocturnal hemoglobinuria (PNH). Read more: https://t.co/e5J3VlARvK @Novartis #FDA #FABHALTA #PNH #ParoxysmalNocturnalHemoGlobinuria #CareAboutRare #FDAApproved
-
-
Mashup Score: 40
Ad hoc announcement pursuant to Art. 53 LR Ad hoc announcement pursuant to Art. 53 LR Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.
Source: www.novartis.comCategories: General Medicine News, NephrologyTweet-
The age of complements is advancing https://t.co/n5AGJ3xkFo Coming soon to a #KidneyWk LBCT I presume...
-
-
Mashup Score: 21FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade - 1 year(s) ago
FDA approval based on robust Phase III data in which Cosentyx® (secukinumab) showed rapid relief from symptoms of hidradenitis suppurativa (HS) as early as Week 21As the only IL-17A inhibitor approved for HS, Cosentyx offers a meaningful new treatment option that demonstrated reductions in inflammatory nodules and abscesses, and flares2HS is a chronic, progressive and often painful disease that may affect 1 in 100 people worldwide3 Basel, October 31, 2023 — Novartis, a global leader in immuno-dermatology and rheumatology, announced today that the US Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults. Cosentyx is the only FDA-approved fully human biologic that directly inhibits interleukin-17A (IL-17A), a cytokine believed to be involved in the inflammation of HS.2 Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide
Source: www.novartis.comCategories: General Medicine News, General HCPsTweet-
FDA has approved secukinumab (Cosentyx) for use in adults w/ moderate to severe hidradenitis suppurativa. Recommended dose is 300 mg SC @ wk 0, 1, 2, 3 and 4 and then every 4 weeks thereafter. https://t.co/Pi6RbDbroG https://t.co/AWhbVj2QGa
-
-
Mashup Score: 55
Ad hoc announcement pursuant to Art. 53 LR Ad hoc announcement pursuant to Art. 53 LR Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.
Source: www.novartis.comCategories: General Medicine News, General HCPsTweet-
More promising results for the treatment of IgA nephropathy - significant reduction in proteinuria with atrasentan at a 36 week interim analysis in the ALIGN trial https://t.co/WMEVcvgYFn
-
-
Mashup Score: 1FDA approves Novartis Cosentyx® as first intravenous (IV) formulation interleukin-17A antagonist for rheumatic diseases - 1 year(s) ago
First new intravenous (IV) treatment option in six years for adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA)1-6 Cosentyx® (secukinumab) administered via IV infusion offers healthcare providers choice and flexibility to tailor treatment to their patients’ unique needs With both IV and subcutaneous formulations, Cosentyx can now help a broader range of PsA, AS and nr-axSpA patients manage their condition EAST HANOVER, N.J., Oct.
Source: www.novartis.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
FDA has approved IV secukinumab (Cosentyx), an IL-17 inhibitor for use in adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). https://t.co/XiikNr3hWO https://t.co/Xd66zgvoDv
-
-
Mashup Score: 1FDA approves Novartis Cosentyx® as first intravenous (IV) formulation interleukin-17A antagonist for rheumatic diseases - 1 year(s) ago
First new intravenous (IV) treatment option in six years for adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA)1-6 Cosentyx® (secukinumab) administered via IV infusion offers healthcare providers choice and flexibility to tailor treatment to their patients’ unique needs With both IV and subcutaneous formulations, Cosentyx can now help a broader range of PsA, AS and nr-axSpA patients manage their condition EAST HANOVER, N.J., Oct.
Source: www.novartis.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
FDA has approved IV secukinumab (Cosentyx), an IL-17 inhibitor for use in adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). https://t.co/48QLLoMvUk https://t.co/mf4IBVLZD9
-
-
Mashup Score: 6
Ad hoc announcement pursuant to Art. 53 LR Ad hoc announcement pursuant to Art. 53 LR Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.
Source: www.novartis.comCategories: Latest Headlines, NephrologyTweet-
The age of complements is advancing https://t.co/n5AGJ3xkFo Coming soon to a #KidneyWk LBCT I presume...
-
Yeah. $NVS buying Morphosys for close to $3B. Smoke=fire here https://t.co/gvgCfZqR1r